

PRESS RELEASE

21 March 2025 08:00:00 CET

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Saniona enters into agreements on guarantee commitments free of charge in the ongoing exercise of warrants series TO 4

Saniona AB ("Saniona" or the "Company") today announces that the Company has agreed on guarantee commitments (so-called "top-down guarantees") in the ongoing exercise of warrants series TO 4 ("TO 4"). The exercise period for TO 4 commenced on 18 March 2025 and will continue until 1 April 2025. The guarantee commitments comprise a total of approximately SEK 11.5 million, corresponding to approximately 10 percent of the issue proceeds that the Company can receive through the exercise of TO 4. The outcome of the exercise of TO 4 and the amount of utilized guarantee commitments will be announced on or around 3 April 2025.

Saniona has, in connection with the ongoing exercise of TO 4, agreed on top guarantees with Wilhelm Risberg and Fredrik Lundgren, of approximately SEK 5.75 million each. The guarantee commitments thus comprise a total of approximately SEK 11.5 million, corresponding to approximately 10 percent of the issue proceeds that the Company can receive through the exercise of TO 4.

The guarantee commitments constitute so-called "top-down guarantees", which means that the guarantee commitments will be utilized in case the TO 4 aren't exercised in full, with the guarantee commitments being utilized fully (approximately SEK 11.5 million) if the exercise of TO 4 is at or below 90 per cent and less if the exercise of TO 4 exceeds 90 per cent. Upon exercise of, for example, 95 percent of the TO 4, the guarantee commitments will be executed for the remaining 5 percent up to fully subscribed TO 4. The guarantee commitments are thus added to the current subscription level for TO 4 and are intended to secure the last part of the subscription of the warrant exercise in the event that all TO 4 are not exercised by existing holders.

If the guarantee commitments are executed, the guarantors' subscriptions of shares will in practice take place through a directed share issue, resolved by the board of directors based on the authorization granted by the annual general meeting on 29 May 2024, after the exercise period for TO 4 has ended. Subscription in such directed share issue shall be made at a subscription price corresponding to the determined exercise price for TO 4, i.e. SEK 4.88, and may thus comprise a maximum of 2,355,564 shares in the Company, corresponding to issue proceeds of approximately SEK 11.5 million in total. The outcome of the exercise of TO 4 and the amount of utilized guarantee commitments will be announced through a separate press release by the Company on or around 3 April 2025.

The guarantee commitments have been provided free of charge and have not been secured by advance transaction, bank guarantee or similar arrangement.

Complete terms and conditions for TO 4 are available on the Company's website, www.saniona.com.

Advisers

Vator Securities AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to the Company in connection with the exercise of TO 4. Vator Securities AB is also issuing agent in connection with the exercise of TO 4.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of neurological disorders. Saniona's internal pipeline includes SAN2219, targeting acute repetitive seizures; SAN2355, addressing refractory focal onset seizures; and SAN2465, positioned for major depressive disorders. Saniona has two strategic development collaborations. SAN711 is being prepared for Phase 2 for essential tremor in collaboration with Acadia Pharmaceuticals and tesofensine is out licensed for obesity to Medix, which has submitted a market authorization application (MAA) in Mexico. In addition, Saniona oversees two clinical programs poised for collaboration. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, visit www.saniona.com.

The information was submitted for publication, through the agency of the contact person set out above, on 21 March 2025 at 08.00 CET.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Saniona. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Saniona has only been made through the prospectus published by Saniona on 18 January 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.saniona.com.

Since Saniona is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, www.saniona.com.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market. For more information, visit www.saniona.com.

Attachments

Saniona enters into agreements on guarantee commitments free of charge in the ongoing exercise of warrants series TO 4